GlassScriptPhysician profile
Rachel Stone
NPI 1457800682
$1,152.69
in general payments reported to CMS, 2019-2025
23 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $55.23 · 2024: $525 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $299.90 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $142.66 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Regeneron Healthcare Solutions, INC. | $55.71 | 2023-2024 | Dupixent |
| Exact Sciences Corporation | $54.44 | 2024-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $49.29 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $46.20 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $43.84 | 2024-2025 | |
| Abbvie INC. | $42.24 | 2025 | |
| Lilly USA, LLC | $38.75 | 2024 | Mounjaro, Jardiance |
| Ibsa Pharma INC. | $38.38 | 2025 | Tirosint, Licart, Flector |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.38 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.26 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $36.64 | 2024 | |
| Amgen INC. | $29.97 | 2024-2025 | Evenity |
| Edwards Lifesciences Corporation | $28.87 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $27.41 | 2025 | Azmiro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.03 | 2024 | |
| Abbott Laboratories | $24.77 | 2025 | Eterna |
| Inspire Medical Systems, INC. | $20.65 | 2024 | Inspire |
| Optinose US, INC. | $18.72 | 2024 | |
| Merck Sharp & Dohme LLC | $17.96 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Idorsia Pharmaceuticals US INC | $16.46 | 2024 | Quviviq |
| Tolmar, INC. | $16.16 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.